The connexin 43 carboxyl terminal mimetic peptide αCT1 prompts differentiation of a collagen scar matrix in humans resembling unwounded skin

Phase II clinical trials have reported that acute treatment of surgical skin wounds with the therapeutic peptide alpha Connexin Carboxy‐Terminus 1 (αCT1) improves cutaneous scar appearance by 47% 9‐month postsurgery. While Cx43 and ZO‐1 have been identified as molecular targets of αCT1, the mode‐of‐...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The FASEB journal 2021-08, Vol.35 (8), p.e21762-n/a, Article 21762
Hauptverfasser:	Montgomery, Jade, Richardson, William J., Marsh, Spencer, Rhett, J. Matthew, Bustos, Francis, Degen, Katherine, Ghatnekar, Gautam S., Grek, Christina L., Jourdan, L. Jane, Holmes, Jeffrey W., Gourdie, Robert G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biochemistry & Molecular Biology Biology Cell Biology Cell Differentiation - drug effects Cicatrix - metabolism Cicatrix - pathology clinical trial computational model Connexin 43 - metabolism Cx43 Dermis - metabolism Extracellular Matrix - metabolism Female Fibroblasts - metabolism Guinea Pigs Humans Life Sciences & Biomedicine Life Sciences & Biomedicine - Other Topics Male peptide therapeutic Peptides - pharmacology Rats Rats, Sprague-Dawley scar mitigation Science & Technology skin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!